Companies › Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Meropenem-Vaborbactam Beta-lactam antibiotic combined with a beta-lactamase inhibitor; meropenem is a carbapenem | DDAH1 | Phase 2 | Acute Pyelonephritis | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06672978 | Meropenem-Vaborbactam | Phase 2 | Acute Pyelonephritis | Infectious disease | Jan 2027 |
–
Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.